News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

OXiGENE (OXGN) To Present Phase I Data Demonstrating Antitumor Activity Of OXi4503 In Patients With Acute Myeloid Leukemia And Myelodysplastic Syndromes



11/18/2013 9:02:27 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SOUTH SAN FRANCISCO, Calif., Nov. 18, 2013 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced that data from a Phase 1 study of its dual-mechanism vascular disrupting agent OXi4503, demonstrating antitumor activity in patients with relapsed and refractory acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), will be presented at the Annual Meeting of the American Society of Hematology (ASH) being held in New Orleans, December 7-10, 2013.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES